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Phase II Study of Belinostat (PXD101), a Histone
Deacetylase Inhibitor, for Second Line Therapy of
Advanced Malignant Pleural Mesothelioma
Suresh S. Ramalingam, MD,* Chandra P. Belani, MD,† Christopher Ruel, MS,‡ Paul Frankel, PhD,‡
Barbara Gitlitz, MD,§ Marianna Koczywas, MD,‡ Igor Espinoza-Delgado, MD,
and David Gandara, MD¶
Background: Belinostat (PXD 101) is a novel inhibitor of class I
and II histone deacetylases. This class of compounds has demon-
strated anticancer activity in malignant mesothelioma. We con-
ducted a phase II study of belinostat in patients with relapsed
malignant pleural mesothelioma.
Methods: Patients with advanced mesothelioma, progression with
one prior chemotherapy regimen and Eastern Cooperative Oncology
Group performance status 0–2 were eligible. Belinostat was admin-
istered at 1000 mg/m2 intravenously over 30 minutes on days 1–5 of
every 3 week cycle. The primary end point was response rate. The
Simon two-stage design was used. Disease assessments were per-
formed every two cycles.
Results: Thirteen patients were enrolled. Baseline characteristics
were: median age of 73 years; Eastern Cooperative Oncology Group
performance status 0 (n  4), 1 (8) and 2 (1). A median of two
cycles of therapy were administered. Disease stabilization was seen
in two patients. No objective responses were noted and the study did
not meet criteria to proceed to the second stage of accrual. Median
survival was 5 months with a median progression-free survival of 1
month. Salient toxicities included nausea, emesis, fatigue, and con-
stipation. One patient died as a consequence of cardiac arrhythmia
which was deemed ‘possibly’ related to therapy.
Conclusions: Belinostat is not active as monotherapy against recur-
rent malignant pleural mesothelioma. Evaluation of combination
strategies or alternate dosing schedules may be necessary for further
development of this novel agent in mesothelioma.
Key Words: Mesothelioma, Histone deacetylase inhibition, Beli-
nostat, PXD 101.
(J Thorac Oncol. 2009;4: 97–101)
Approximately 2000 cases of malignant pleural mesothe-lioma (MPM) are diagnosed annually in the United
States.1 It is a locally invasive tumor that is associated with a
5-year survival rate of less than 15%.2 Complete surgical
resection is the only treatment modality that is associated
with a curative potential. However, majority of the patients
present with advanced stage disease and therefore are not
candidates for aggressive curative surgical resection. The
median survival for such patients is approximately 6 months
with supportive care measures alone.3 For patients with
unresectable disease, systemic chemotherapy is the treatment
of choice. The combination of pemetrexed and cisplatin is the
Food and Drug Administration-approved regimen for the
treatment of patients with advanced MPM. The median sur-
vival of 13 months and a 1-year survival rate of 56% with the
combination were superior when compared with mono-
therapy with cisplatin in a randomized phase III study.4 There
is currently no approved therapy for patients who experience
disease progression following therapy with pemetrexed-plat-
inum combination.
Histone deacetylase (HDAC) inhibitors are a novel
class of agents that have demonstrated promising anticancer
activity against a variety of malignancies. Histones, the core
nucleosomal proteins, exist in either a transcriptionally active
acetylated form or an inactive deacetylated state. The dy-
namic equilibrium between the acetylated and nonacetylated
states is mediated by histone acetyl transferase and histone
deacetylase. HDAC inhibition results in histone acetylation,
which leads to the expression of genes associated with cell
cycle arrest and tumor suppression.5–7 In addition to inhibi-
tion of histone deacetylation, HDAC inhibitors also mediate
anticancer effects by acetylation of a number of nonhistone
proteins. Vorinostat, a HDAC inhibitor, has been approved
by the Food and Drug Administration for the treatment of
refractory cutaneous T-cell lymphoma.
Early phase clinical trials with vorinostat have demon-
strated promising anticancer activity in patients with malig-
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nant mesothelioma.8 This has prompted a large randomized
study that compares the efficacy of vorinostat with best
supportive care in mesothelioma patients who have pro-
gressed following prior standard chemotherapy. HDAC in-
hibitors have been documented to enhance the susceptibility
of mesothelioma cell lines to tumor necrosis factor-related
apoptosis-inducing ligand.9 In addition, HDAC inhibitors
block angiogenic signaling mediated by vascular endothelial
growth factor as a result of their effect on acetylation of
hypoxia inducing factor 1 alpha.10 Notably, patients with
mesothelioma have higher levels of circulating vascular en-
dothelial growth factor compared with other solid tumors.11
Belinostat is a novel, low molecular weight hydroxamic
acid HDAC inhibitor. It exerts anticancer activity against a
variety of human tumor cell lines.12–14 Preclinical studies
have also documented a strong association between the anti-
cancer effects of belinostat with increased histone acetyla-
tion.14 Based on these data, belinostat is now currently under
evaluation for the treatment of a variety of solid organ and
hematological malignancies. The recommended dose of be-
linostat for phase II studies is 1000 mg/m2 administered IV
over 30 minutes for 5 consecutive days of each 21-day
cycle.15 The dose-limiting toxicities are diarrhea and fatigue.
In the phase I study of belinostat, disease stabilization was
noted in a variety of solid tumors. We conducted this phase II
study to evaluate the anticancer activity of belinostat in
patients with malignant mesothelioma following progressive
disease with standard chemotherapy.
PATIENTS AND METHODS
Patient Eligibility
Patients with histologic confirmation of MPM, age18
years, Eastern Cooperative Oncology Group performance
status (PS) of 0–2, and measurable disease were eligible. No
more than one prior systemic chemotherapy regimen was
allowed for study entry. Qualifying laboratory criteria were:
leukocytes 3000/l; absolute neutrophil count 1500/l;
platelet count 100,000/l; serum total bilirubin  institu-
tional upper limit of normal (ULN); serum transminases
2.5  ULN; and serum creatinine  ULN. Patients with
serum creatinine levels ULN were eligible if their creati-
nine clearance was 50 ml/min/1.73 m2. Other pertinent
exclusion criteria were: history of long QT syndrome; con-
comitant medications that might prolong QT interval; signif-
icant cardiac disease; need for active antiarrhythmic therapy;
use of valprioc acid, a known HDAC inhibitor and the
presence of active intercurrent infections. Pregnant women
were excluded, and subjects with reproductive potential were
required to use contraception. At least 3 weeks should have
elapsed since any prior chemotherapy or radiotherapy (6
weeks for nitrosoureas or mitomycin C) for study eligibility.
All patients provided written informed consent before enroll-
ment. The study was approved by the Institutional Review
Board at each participating site.
Treatment Plan
Belinostat was administered as a 30-minute IV infusion
on days 1 to 5 of each 21-day treatment cycle. All treatments
were given in the outpatient setting. No premedications were
necessary on a routine basis. All qualifying laboratory criteria
were to be met before initiation of each cycle of therapy.
Toxicities related to therapy should have recovered to grade
1 or less before each new cycle. Treatment cycles could be
delayed for a maximum of 2 weeks to allow for recovery
from toxicity. An electrocardiogram was obtained at the end
of infusion of belinostat on day 5 of each cycle to evaluate for
changes in QTc interval.
Treatment cycles were continued for a maximum of six
cycles and were discontinued earlier for disease progression,
unacceptable toxicity, withdrawal of informed consent, or
other intercurrent illness that altered the risk-benefit ratio of
study therapy.
Toxicity was graded using the National Cancer Institute
Common Terminology Criteria version 3.0. All patients who
received at least one dose of the experimental agent were
considered evaluable for toxicity. The dose of belinostat was
modified for patients who experienced grade 3 or higher
nonhematological toxicity in 25% decrements. Similar dose
reduction was done for grade 4 hematological toxicities or
grade 3 neutropenia associated with fever. For patients who
experience grade 4 QTc prolongation, belinostat was to be
discontinued permanently. All dose reductions were perma-
nent and no more than two dose reductions were allowed for
each patient. Those who required more than two dose reduc-
tions were to be removed from the study.
Patient Evaluation
Pretreatment evaluations were: history and physical
examination (H&P), assessment of PS, complete blood count
(CBC), hepatic and renal function tests. An electrocardio-
gram was obtained at baseline. Women of reproductive age
underwent a serum pregnancy test. Patients were evaluated
weekly with CBC, hepatic and renal function tests during the
first cycle. Serum chemistry tests and CBC were done on day
1 of each cycle from cycle 2 onwards. Radiologic studies to
assess response were performed after every two cycles of
therapy. H&P and assessment of PS were done before initi-
ation of each cycle. Responses were assessed with Respon-
sive Evaluation Criteria in Solid Tumors criteria.16
Statistical Considerations
The primary end point of the study was to determine the
response rate associated with belinostat in patients with
recurrent or refractory MPM. Secondary endpoints included
the assessment of safety profile, median progression-free
survival and overall survival associated with belinostat mono-
therapy.
Since there are no proven treatment options for patients
with mesothelioma in the second line setting, a response rate
of 20% with belinostat in this study would warrant further
evaluation, where as a response rate of 5% would be
considered uninteresting. The two stage optimum design by
Simon was used.17 In the first stage, 12 patients were to be
accrued. At least 1 objective response out of 12 was neces-
sary to proceed to the full accrual of 37 total patients. Four (4)
or more responses out of 37 patients would be considered
evidence warranting further study of the regimen providing
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other factors, such as toxicity and survival, also appeared
favorable. With this sample size, the probability of falsely
declaring a regimen with a 5% response rate as warranting
further study is 0.10 (alpha) and the probability of correctly
declaring an agent with a 20% response rate as warranting
further study is 0.90 (power). Patients who completed one
cycle of therapy, terminated treatment for reasons of toxicity,
or progressed prior to completion of one cycle of therapy,
were included in the analysis of tumor response, and in any
decision to terminate the study early. With the total sample
size of 37 evaluable patients, the 95% confidence interval for
the response rate had a half-width of  17% or less.
RESULTS
Baseline Characteristics
A total of 13 patients were enrolled to the study
between June 2006 and June 2007 (Table 1). The median age
was 74 years (range, 27–82). Five out of the 13 patients were
females. All patients were of Caucasian ethnicity. The PS at
baseline was as follows: Eastern Cooperative Oncology
Group 0: 4 pts; 1–8 pts and 2–1 pt. One patient had prior
radiotherapy to his chest and 12 patients had received prior
chemotherapy. One treatment-naive patient who refused che-
motherapy was enrolled to the study as allowed by the
protocol. Seven patients had the epithelial subtype of me-
sothelioma. Seven patients had received the combination of
cisplatin and pemetrexed as front-line therapy and 4 patients
had been treated with a pemetrexed-containing regimen with-
out cisplatin. Two patients had achieved a partial response to
first line therapy and four had stable disease as the best
response. The remainder of the patients was refractory to
frontline chemotherapy.
Treatment Delivery and Toxicity
A median of 2 cycles of treatment were administered
(range, 1–6). Disease progression was the most common
reason for discontinuation of treatment (n  7). One patient
completed the protocol-specified maximum of six cycles of
therapy. A 81 years old male patient with prior history of
valvular heart disease was hospitalized for rapid atrial fibril-
lation after day 2 of belinostat infusion during cycle 1. He
was noted to have a non-Q wave myocardial infarction and
required mechanical ventilation for heart failure. He subse-
quently developed ventilator-associated pneumonia and had a
prolonged hospital course. The family opted to discontinue
mechanical ventilation and the patient died shortly there after.
One patient who received four cycles of therapy decided to
discontinue therapy for nontoxicity-related personal reasons.
The commonly noted toxicities related to therapy were an-
orexia, nausea, and fatigue (Table 2).
Efficacy
All thirteen patients were evaluable for response assess-
ment. Two patients had stable disease, but there were no
partial responses. Based on the first stage response analysis,
the study did not meet the criteria to continue to the next stage
of accrual. The median progression-free survival was 1
month and the median overall survival was 5 months (Figure
1). Three patients only received one cycle of therapy and
were removed from study due to symptomatic or radiologic
progression. Of the two patients with stable disease, one was
TABLE 1. Patient Baseline Characteristics
Patient characteristic n
Patients enrolled 13
Male 8
Median age 73 (27–82)
Performance status (ECOG)
0 4
1 8
2 1
Prior therapy
Chemotherapy 12
Cisplatin-pemetrexed 7
Carboplatin-pemetrexed 4
Cisplatin-gemcitabine 1
Radiotherapy 1
Histology
Epithelial subtype 7
Sarcomatoid subtype 1
NOS, Not otherwise
specified
5
ECOG, Eastern Cooperative Oncology Group.
TABLE 2. Toxicitya
Toxicityb Grade 2 (n) Grade 3 (n) Grade 4 (n)
Hematological
Hemoglobin 6
Lymphopenia 1
Nonhematological
Albumin 1
Allergic reaction 1
Anorexia 2
AST 1
Constipation 2
Creatinine 1
Sweating 1
Dyspnea 3 1 1
Fatigue 2
Glucose (hyperglycemia) 6
Hypoxia 1
Hypotension 1
Infection 2
Nausea 2
Pain 1
Sodium (hyponatremia) 3
Supraventricular
arrhythmia NOS
2 1
AST, aspartate transaminase.
a Represents the number of patients with toxicity of grade 1 experienced during
the course of study. Only those adverse events those were definite, probable, possible or
likely related to treatment are included in the table.
b Toxicity was graded by NCI CTC version 3.0.
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refractory to prior chemotherapy and the other had stable
disease as the best response.
DISCUSSION
HDAC inhibitors are a new class of anticancer agents
and are being evaluated for the treatment of a variety of
malignancies. Malignant mesothelioma is a refractory neo-
plasm that does not have any proven treatment options for
progressive disease following combination chemotherapy
with cisplatin and pemetrexed. The outcome for these pa-
tients is poor and is therefore an unmet medical need. The
promising single agent activity noted with vorinostat in this
setting prompted our phase II study to evaluate the anticancer
activity of belinostat, another novel HDAC inhibitor, for
second line therapy for malignant mesothelioma. Our study
failed to note objective tumor response in any of the 13
patients enrolled to the first stage of accrual and was therefore
closed for lack of efficacy. Encouraging disease stabilization
was noted in 2 patients who received therapy for 4 and 6
cycles respectively. Belinostat was tolerated well at the dose
and schedule used for the study. Some of the common
adverse events noted in our study such as anemia, hypergly-
cemia and hyponatremia have all been documented with the
use of belinostat. Three patients had supraventricular tachy-
cardia during the course of the study. While this toxicity has
also been reported with the use of belinostat, other factors
such as hypoxia, concomitant medications and prior cardiac
disease could have also been the causal factors.
Since the time of initiation of our study, new data have
become available with HDAC inhibitor monotherapy in var-
ious solid organ tumors. In a phase II study for patients with
metastatic breast cancer, vorinostat was not associated with
single agent activity.18 Similarly, in a study for patients with ad-
vanced head and neck cancer, no confirmed responses were
noted in a cohort of 12 patients who were treated with
vorinostat as monotherapy.19 Vorinostat also failed to dem-
onstrate single agent activity in 14 patients with advanced
stage non-small cell lung cancer (NSCLC) that had pro-
gressed following standard treatment options.20 Taken to-
gether, these results demonstrate that HDAC inhibitors are
not active as monotherapy in the treatment of solid tumors.
Despite this, certain aspects of belinostat and our study
patient characteristics warrant further mention as potential
reasons behind the negative results of our study. Our study
included a patient group with aggressive disease as evidenced
by the fact that half the patients had progressive disease
within 1 month of initiation of study treatment. The biologic
aggressiveness of the disease could have rendered this patient
population to be resistant to any therapy. Furthermore, vori-
nostat and other HDAC inhibitors that are administered orally
are being given on a continuous daily schedule as mono-
therapy. Belinostat is an intravenously administered agent
and has been developed on an intermittent schedule (5 con-
tinuous days of therapy every 3 weeks). Pharmacodynamic
modulation of the targets with belinostat has been docu-
mented to last for approximately 24 hours after exposure to
the drug.14 Therefore, under the current schedule, the tumors
are exposed to the drug for only a third of the duration of each
treatment cycle. This could also have contributed to the lack
of efficacy noted with belinostat in our study. An oral for-
mulation of the agent is under development and will be
conducive for continuous administration in future studies.
Though inactive as monotherapy, HDAC inhibitors
have demonstrated promising activity when given in combi-
nation with cytotoxic or other targeted agents. In a phase I
study, the combination of vorinostat with carboplatin and
paclitaxel resulted in robust anticancer activity in patients
with advanced NSCLC. An ongoing randomized phase II/III
study will evaluate if the addition of vorinostat improves the
survival of NSCLC patients treated with carboplatin and
paclitaxel. Belinostat has also demonstrated promising activ-
ity in combination with carboplatin and paclitaxel in solid
tumors. A randomized clinical trial is currently underway for
patients with carcinoma of unknown primary to determine if
the addition of belinostat to carboplatin and paclitaxel results
in improved survival.
Our study included collection of archived tumor tissues
to evaluate for potential biomarker evaluation. However, the
planned exploratory studies were not conducted in light of the
lack of single agent activity. Sequential pre- and posttreat-
ment biopsies could have been helpful to establish if the
experimental agent effected the changes on target proteins as
anticipated.
In summary, belinostat is not active as monotherapy
when given on the present schedule for second line therapy
for MPM. Further studies should evaluate novel combina-
tions of HDAC inhibitors with either cytotoxic agents or
other molecularly targeted agents for the treatment of this
disease.
ACKNOWLEDGMENTS
Supported by NCI NO1 CM-62209.
REFERENCES
1. Connelly RR, Spirtas R, Myers MH, et al. Demographic patterns for
mesothelioma in the United States. J Natl Cancer Inst 1987;78:1053–
1060.
2. Zellos LS, Sugarbaker DJ. Multimodality treatment of diffuse malignant
pleural mesothelioma. Semin Oncol 2002;29:41–50.
3. Antman K, Shemin R, Ryan L, et al. Malignant mesothelioma: prog-
nostic variables in a registry of 180 patients, the Dana-Farber Cancer
FIGURE 1. Kaplan Meier curve for overall and progression-
free survival.
Ramalingam et al. Journal of Thoracic Oncology • Volume 4, Number 1, January 2009
Copyright © 2008 by the International Association for the Study of Lung Cancer100
Institute and Brigham and Women’s Hospital experience over two
decades, 1965–1985. J Clin Oncol 1988;6:147–153.
4. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of
pemetrexed in combination with cisplatin versus cisplatin alone in
patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:
2636–2644.
5. Kelly WK, Richon V, Troso-Sandoval T. Suberoylanilide hydroxamic
acid (SAHA), a Histone Deacetylase inhibitor: Biologic activity without
toxicity. Proc Am Soc Clin Oncol 2001;20:A344.
6. Richon VM, Emiliani S, Verdin E, et al. A class of hybrid polar inducers
of transformed cell differentiation inhibits histone deacetylases. Proc
Natl Acad Sci U S A 1998;95:3003–3007.
7. Yoshida M, Kijima M, Akita M, et al. Potent and specific inhibition of
mammalian histone deacetylase both in vivo and in vitro by trichostatin
A. J Biol Chem 1990;265:17174–17179.
8. Krug LM, Curley T, Schwartz L, et al. Potential role of histone
deacetylase inhibitors in mesothelioma: clinical experience with sub-
eroylanilide hydroxamic acid. Clin Lung Cancer 2006;7:257–261.
9. Neuzil J, Swettenham E, Gellert N. Sensitization of mesothelioma to
TRAIL apoptosis by inhibition of histone deacetylase: role of Bcl-xL
down-regulation. Biochem Biophys Res Commun 2004;314:186–191.
10. Deroanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhib-
itors as anti-angiogenic agents altering vascular endothelial growth
factor signaling. Oncogene 2002;21:427–436.
11. Linder C, Linder S, Munck-Wikland E, et al. Independent expression of
serum vascular endothelial growth factor (VEGF) and basic fibroblast
growth factor (bFGF) in patients with carcinoma and sarcoma. Antican-
cer Res 1998;18:2063–2068.
12. Buckley MT, Yoon J, Yee H, et al. The histone deacetylase inhibitor
belinostat (PXD101) suppresses bladder cancer cell growth in vitro and
in vivo. J Transl Med 2007;5:49.
13. Qian X, Ara G, Mills E, et al. Activity of the histone deacetylase
inhibitor belinostat (PXD101) in preclinical models of prostate cancer.
Int J Cancer 2008;122:1400–1410.
14. Plumb JA, Finn PW, Williams RJ, et al. Pharmacodynamic response and
inhibition of growth of human tumor xenografts by the novel histone
deacetylase inhibitor PXD101. Mol Cancer Ther 2003;2:721–728.
15. Steele NL, Plumb JA, Vidal L, et al. A phase 1 pharmacokinetic and
pharmacodynamic study of the histone deacetylase inhibitor belinostat in
patients with advanced solid tumors. Clin Cancer Res 2008;14:804–
810.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to
evaluate the response to treatment in solid tumors. European Organiza-
tion for Research and Treatment of Cancer, National Cancer Institute of
the United States, National Cancer Institute of Canada. J Natl Cancer
Inst 2000;92:205–216.
17. Simon R. Optimal two-stage designs for phase II clinical trials. Control
Clin Trials 1989;10:1–10.
18. Luu TH, Morgan RJ, Leong L, et al. A phase II trial of virnostat
(suberoylanilide hydroxamic acid) in metastic breast cancer: A Califor-
nia Consortium study. Clin Cancer Res 2008;14:7138–7142.
19. Blumenschein GR, Jr, Kies MS, Papadimitrakopoulou VA, et al. Phase
II trial of the histone deacetylase inhibitor vorinostat (Zolinza, suberoy-
lanilide hydroxamic acid, SAHA) in patients with recurrent and/or
metastatic head and neck cancer. Invest New Drugs 2008;26:81–87.
20. Traynor AM, Dubey S, Eickhoff J, et al. A phase II study of vorinostat
(NSC 701852) in patients (pts) with relapsed non-small cell lung cancer
(NSCLC). J Clin Oncol 2007;25(18S): Abstract 18044.
Journal of Thoracic Oncology • Volume 4, Number 1, January 2009 Phase II Study of Belinostat
Copyright © 2008 by the International Association for the Study of Lung Cancer 101
